FDA approves Ryoncil for steroid-refractory acute graft-versus-host after allo-HSCT
The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approved for ...
Zacks.com on MSN8d
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft ...
clinicaladvisor.com1d
Mesenchymal Stromal Cell Therapy Ryoncil Gets FDA Approval
The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...
Mesoblast has received FDA approval for its drug Ryoncil
Mesoblast shareholders are sitting on as much as 10-fold gains for the year, after the US Food and Drug Administration ...
Cure Today9d
Ryoncil Receives FDA Approval for Children With GVHD
This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.
Yahoo Finance8d
FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment
Mesoblast has gained US Food and Drug Administration (FDA) approval for its mesenchymal stromal cell (MSC) therapy, Ryoncil ...
MyChesCo on MSN8h
FDA Approves Groundbreaking Cell Therapy for Life-Threatening Pediatric Disease
A seismic shift in pediatric medical care has arrived with the FDA’s approval of Ryoncil (remestemcel-L-rknd), a ...
Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 ...
Mesoblast awarded FDA approval for Ryoncil
Mesoblast (ASX:MSB) has received approval from the US Food and Drug Administration (FDA) for Ryoncil (remestemcel-L), making ...
Mesoblast RYONCIL becomes first FDA-approved mesenchymal stromal cell therapy
Mesoblast (MESO) announced the FDA approved Ryoncil, remestemcel-L, as the first mesenchymal stromal cell, MSC, therapy in ...
Cancer Therapy Advisor8d
Ryoncil Approved to Treat GVHD in Pediatric Patients
The FDA has approved Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute GVHD in pediatric patients age 2 months and older.
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
Mesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in ...